FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054073281> ?p ?o ?g. }

• W2054073281 abstract "Background: Pre-clinical and clinical studies demonstrate that combining Cy with granulocyte-macrophage colony-stimulating factor (GM-CSF) secreting irradiated allogeneic pancreatic tumor cells (pancGVAX) enhances clinical and vaccine induced anti-tumor immune responses. The mechanism is thought to occur by inhibiting suppressor T-cell activity and promoting a type 1 cytotoxic immune response by promoting dendritic cell (DC) activation. Additional pre-clinical evidence support monoclonal antibodies such as Cetuximab that target growth factor receptors (GFRs) in synergistic anti-tumor immune responses. It is estimated that >70% of pancreatic cancers overexpress EGFR. This supports a role for combinatorial immunotherapies in advanced pancreatic cancer. Methods: Sixty patients with advanced pancreatic cancer who progressed on, or refused, first line standard therapy received six cycles of Cy (250 mg/m2) on day 0, pancGVAX (5x108 cells) on day 1, and Cetuximab on days 1, 8 and 15 (initial dose of 400 mg/m2 and subsequent doses of 250 mg/m2) every three weeks. Patients who experienced grade 3 Cetuximab hypersensitivity reactions continued to receive Cy and pancGVAX treatments without further Cetuximab. Serum cytokines and immunoglobulins were analyzed by ELISA and serum cell populations were evaluated using flow cytometry. Results: Twelve out of the 60 patients were hypersensitive to Cetuximab. Median survival was 4.5 months overall. Survival in the hypersensitivity group was 7.1 versus 4.1 months in the non-hypersensitivity group (p=0.026). Baseline characteristics were similar except for the increased number of metastatic disease sites in the hypersensitivity group (2 or more, 100% versus 69%, p=0.027). There was a significant difference in the association between serum IgE levels at enrollment and overall survival for hypersensitive as compared to non-hypersensitive patients (p=0.004). Among hypersensitive patients, higher serum IgE levels at enrollment was associated with increased risk of death (p=0.019, HR =1.05, 95% CI: 1.009 to 1.099). The baseline serum IgE level was not predictive of overall survival for non-hypersensitive patients (p=0.75); however, higher serum IgE levels following the first vaccine was associated with increased risk (p=0.010, HR = 1.026, 95% CI: 1.006 to 1.046). Lower levels of surface IgE bound to plasmacytoid DCs (pDCs), but not monocytoid DCs or basophils, correlated with overall survival both at baseline (p=0.019) and after vaccination (p=0.006). Overall survival also correlated with lower levels of serum IL-6 (p=0.031) and IL-8 (p=0.043). This suggests that a pDC-mediated skewing towards type 2 inflammatory responses is associated with poor prognosis in these patients. Conclusions: Prolonged survival in advanced pancreatic cancer patients correlated with IgE-independent hypersensitivity to Cetuximab. IgE mediated type 2 inflammatory responses are associated with poor prognosis in patients receiving immunotherapy. Blockade of IgE may enhance the efficacy of immunotherapy in pancreatic cancer patients. Citation Format: Julie Ng, Jennifer Uram, Beth Onners, Barbara Biedrzycki, Elizabeth Sugar, Sara Solt, Todd Armstrong, Dung Le, Lei Zheng, John Schroeder, Elizabeth Jaffee, Daniel Laheru. IgE-independent hypersensitvity reactions are associated with prolonged survival in advanced pancreatic cancer patients receiving a GM-CSF cell-based vaccine plus cyclophosphamide (Cy) and cetuximab. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; Dec 2-5, 2012; Miami, FL. Philadelphia (PA): AACR; Cancer Res 2013;73(1 Suppl):Abstract nr B27." @default.
• W2054073281 created "2016-06-24" @default.
• W2054073281 creator A5001768193 @default.
• W2054073281 creator A5008032183 @default.
• W2054073281 creator A5011776853 @default.
• W2054073281 creator A5013313440 @default.
• W2054073281 creator A5019056999 @default.
• W2054073281 creator A5033720986 @default.
• W2054073281 creator A5044270602 @default.
• W2054073281 creator A5050642902 @default.
• W2054073281 creator A5058389360 @default.
• W2054073281 creator A5060335470 @default.
• W2054073281 creator A5070162543 @default.
• W2054073281 creator A5087012598 @default.
• W2054073281 date "2013-01-01" @default.
• W2054073281 modified "2023-09-27" @default.
• W2054073281 title "Abstract B27: IgE-independent hypersensitvity reactions are associated with prolonged survival in advanced pancreatic cancer patients receiving a GM-CSF cell-based vaccine plus cyclophosphamide (Cy) and cetuximab." @default.
• W2054073281 doi "https://doi.org/10.1158/1538-7445.tumimm2012-b27" @default.
• W2054073281 hasPublicationYear "2013" @default.
• W2054073281 type Work @default.
• W2054073281 sameAs 2054073281 @default.
• W2054073281 citedByCount "0" @default.
• W2054073281 crossrefType "proceedings-article" @default.
• W2054073281 hasAuthorship W2054073281A5001768193 @default.
• W2054073281 hasAuthorship W2054073281A5008032183 @default.
• W2054073281 hasAuthorship W2054073281A5011776853 @default.
• W2054073281 hasAuthorship W2054073281A5013313440 @default.
• W2054073281 hasAuthorship W2054073281A5019056999 @default.
• W2054073281 hasAuthorship W2054073281A5033720986 @default.
• W2054073281 hasAuthorship W2054073281A5044270602 @default.
• W2054073281 hasAuthorship W2054073281A5050642902 @default.
• W2054073281 hasAuthorship W2054073281A5058389360 @default.
• W2054073281 hasAuthorship W2054073281A5060335470 @default.
• W2054073281 hasAuthorship W2054073281A5070162543 @default.
• W2054073281 hasAuthorship W2054073281A5087012598 @default.
• W2054073281 hasConcept C121608353 @default.
• W2054073281 hasConcept C126322002 @default.
• W2054073281 hasConcept C143998085 @default.
• W2054073281 hasConcept C159654299 @default.
• W2054073281 hasConcept C203014093 @default.
• W2054073281 hasConcept C2777701055 @default.
• W2054073281 hasConcept C2779998722 @default.
• W2054073281 hasConcept C2780210213 @default.
• W2054073281 hasConcept C542903549 @default.
• W2054073281 hasConcept C71924100 @default.
• W2054073281 hasConcept C8891405 @default.
• W2054073281 hasConceptScore W2054073281C121608353 @default.
• W2054073281 hasConceptScore W2054073281C126322002 @default.
• W2054073281 hasConceptScore W2054073281C143998085 @default.
• W2054073281 hasConceptScore W2054073281C159654299 @default.
• W2054073281 hasConceptScore W2054073281C203014093 @default.
• W2054073281 hasConceptScore W2054073281C2777701055 @default.
• W2054073281 hasConceptScore W2054073281C2779998722 @default.
• W2054073281 hasConceptScore W2054073281C2780210213 @default.
• W2054073281 hasConceptScore W2054073281C542903549 @default.
• W2054073281 hasConceptScore W2054073281C71924100 @default.
• W2054073281 hasConceptScore W2054073281C8891405 @default.
• W2054073281 hasLocation W20540732811 @default.
• W2054073281 hasOpenAccess W2054073281 @default.
• W2054073281 hasPrimaryLocation W20540732811 @default.
• W2054073281 hasRelatedWork W2061056565 @default.
• W2054073281 hasRelatedWork W2077072111 @default.
• W2054073281 hasRelatedWork W2082705345 @default.
• W2054073281 hasRelatedWork W2127039405 @default.
• W2054073281 hasRelatedWork W2162592936 @default.
• W2054073281 hasRelatedWork W2275084659 @default.
• W2054073281 hasRelatedWork W2295178911 @default.
• W2054073281 hasRelatedWork W2325702433 @default.
• W2054073281 hasRelatedWork W2392176337 @default.
• W2054073281 hasRelatedWork W2407918516 @default.
• W2054073281 hasRelatedWork W2483562035 @default.
• W2054073281 hasRelatedWork W2499805877 @default.
• W2054073281 hasRelatedWork W2564960455 @default.
• W2054073281 hasRelatedWork W2572235850 @default.
• W2054073281 hasRelatedWork W2781635391 @default.
• W2054073281 hasRelatedWork W2947405510 @default.
• W2054073281 hasRelatedWork W3013356138 @default.
• W2054073281 hasRelatedWork W3204424520 @default.
• W2054073281 hasRelatedWork W3206884865 @default.
• W2054073281 hasRelatedWork W2318533719 @default.
• W2054073281 isParatext "false" @default.
• W2054073281 isRetracted "false" @default.
• W2054073281 magId "2054073281" @default.
• W2054073281 workType "article" @default.